Financhill
Sell
45

BTMD Quote, Financials, Valuation and Earnings

Last price:
$4.18
Seasonality move :
-12.43%
Day range:
$3.95 - $4.18
52-week range:
$3.04 - $8.43
Dividend yield:
0%
P/E ratio:
6.72x
P/S ratio:
0.72x
P/B ratio:
--
Volume:
100.3K
Avg. volume:
119.1K
1-year change:
-50.96%
Market cap:
$129.1M
Revenue:
$197.2M
EPS (TTM):
$0.61

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BTMD
Biote
$49.5M $0.13 0.72% -5.56% $6.40
AMS
American Shared Hospital Services
$7.3M -$0.07 3.32% -92.73% $4.85
ASTH
Astrana Health
$639.1M $0.48 31.44% 19.67% $47.4444
CCEL
Cryo-Cell International
$8M -$0.04 -0.02% -62.5% $8.50
OMCL
Omnicell
$275.3M $0.27 -0.47% 226.21% $43.33
PIII
P3 Health Partners
$359.4M -$0.09 -5.97% -- $8.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BTMD
Biote
$4.10 $6.40 $129.1M 6.72x $0.00 0% 0.72x
AMS
American Shared Hospital Services
$2.55 $4.85 $16.4M 11.59x $0.00 0% 0.59x
ASTH
Astrana Health
$25.2800 $47.4444 $1.2B 35.11x $0.00 0% 0.54x
CCEL
Cryo-Cell International
$4.91 $8.50 $39.7M 498.00x $0.15 13.24% 1.27x
OMCL
Omnicell
$27.78 $43.33 $1.3B 60.39x $0.00 0% 1.14x
PIII
P3 Health Partners
$6.50 $8.00 $21.2M -- $0.00 0% 0.01x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BTMD
Biote
658.33% 2.818 96.45% 1.02x
AMS
American Shared Hospital Services
49.64% 0.006 107.98% 1.71x
ASTH
Astrana Health
35.84% -0.843 32.26% 1.63x
CCEL
Cryo-Cell International
-2873.84% 1.933 36.34% 0.52x
OMCL
Omnicell
21.35% 0.864 20.84% 1.07x
PIII
P3 Health Partners
73.1% -1.778 203.2% 0.34x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BTMD
Biote
$36.4M $9.7M 171.33% -- 41.56% $4.6M
AMS
American Shared Hospital Services
$942K -$866K 2.81% 4.81% -13.12% -$1.5M
ASTH
Astrana Health
$71.3M $20.6M 3.81% 7.09% 2.73% $13.6M
CCEL
Cryo-Cell International
$6.1M $1.5M 122.88% -- 14.2% $644.6K
OMCL
Omnicell
$110.9M -$11.6M 1.24% 1.73% -4.31% $10.2M
PIII
P3 Health Partners
-- -$38.1M -34.43% -53.56% -9.23% -$33.5M

Biote vs. Competitors

  • Which has Higher Returns BTMD or AMS?

    American Shared Hospital Services has a net margin of 28% compared to Biote's net margin of -10.23%. Biote's return on equity of -- beat American Shared Hospital Services's return on equity of 4.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    BTMD
    Biote
    74.26% $0.37 $21.3M
    AMS
    American Shared Hospital Services
    15.41% -$0.10 $53.5M
  • What do Analysts Say About BTMD or AMS?

    Biote has a consensus price target of $6.40, signalling upside risk potential of 56.05%. On the other hand American Shared Hospital Services has an analysts' consensus of $4.85 which suggests that it could grow by 90.2%. Given that American Shared Hospital Services has higher upside potential than Biote, analysts believe American Shared Hospital Services is more attractive than Biote.

    Company Buy Ratings Hold Ratings Sell Ratings
    BTMD
    Biote
    4 0 0
    AMS
    American Shared Hospital Services
    0 0 0
  • Is BTMD or AMS More Risky?

    Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.223%.

  • Which is a Better Dividend Stock BTMD or AMS?

    Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BTMD or AMS?

    Biote quarterly revenues are $49M, which are larger than American Shared Hospital Services quarterly revenues of $6.1M. Biote's net income of $13.7M is higher than American Shared Hospital Services's net income of -$625K. Notably, Biote's price-to-earnings ratio is 6.72x while American Shared Hospital Services's PE ratio is 11.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.72x versus 0.59x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BTMD
    Biote
    0.72x 6.72x $49M $13.7M
    AMS
    American Shared Hospital Services
    0.59x 11.59x $6.1M -$625K
  • Which has Higher Returns BTMD or ASTH?

    Astrana Health has a net margin of 28% compared to Biote's net margin of 1.08%. Biote's return on equity of -- beat Astrana Health's return on equity of 7.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    BTMD
    Biote
    74.26% $0.37 $21.3M
    ASTH
    Astrana Health
    11.5% $0.14 $934.1M
  • What do Analysts Say About BTMD or ASTH?

    Biote has a consensus price target of $6.40, signalling upside risk potential of 56.05%. On the other hand Astrana Health has an analysts' consensus of $47.4444 which suggests that it could grow by 87.68%. Given that Astrana Health has higher upside potential than Biote, analysts believe Astrana Health is more attractive than Biote.

    Company Buy Ratings Hold Ratings Sell Ratings
    BTMD
    Biote
    4 0 0
    ASTH
    Astrana Health
    8 3 0
  • Is BTMD or ASTH More Risky?

    Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 0.842, suggesting its less volatile than the S&P 500 by 15.811%.

  • Which is a Better Dividend Stock BTMD or ASTH?

    Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Biote's is not.

  • Which has Better Financial Ratios BTMD or ASTH?

    Biote quarterly revenues are $49M, which are smaller than Astrana Health quarterly revenues of $620.4M. Biote's net income of $13.7M is higher than Astrana Health's net income of $6.7M. Notably, Biote's price-to-earnings ratio is 6.72x while Astrana Health's PE ratio is 35.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.72x versus 0.54x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BTMD
    Biote
    0.72x 6.72x $49M $13.7M
    ASTH
    Astrana Health
    0.54x 35.11x $620.4M $6.7M
  • Which has Higher Returns BTMD or CCEL?

    Cryo-Cell International has a net margin of 28% compared to Biote's net margin of 4.49%. Biote's return on equity of -- beat Cryo-Cell International's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BTMD
    Biote
    74.26% $0.37 $21.3M
    CCEL
    Cryo-Cell International
    76.59% $0.04 -$523.2K
  • What do Analysts Say About BTMD or CCEL?

    Biote has a consensus price target of $6.40, signalling upside risk potential of 56.05%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 73.12%. Given that Cryo-Cell International has higher upside potential than Biote, analysts believe Cryo-Cell International is more attractive than Biote.

    Company Buy Ratings Hold Ratings Sell Ratings
    BTMD
    Biote
    4 0 0
    CCEL
    Cryo-Cell International
    0 0 0
  • Is BTMD or CCEL More Risky?

    Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.131%.

  • Which is a Better Dividend Stock BTMD or CCEL?

    Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 13.24% to investors and pays a quarterly dividend of $0.15 per share. Biote pays 150.27% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BTMD or CCEL?

    Biote quarterly revenues are $49M, which are larger than Cryo-Cell International quarterly revenues of $7.9M. Biote's net income of $13.7M is higher than Cryo-Cell International's net income of $355.8K. Notably, Biote's price-to-earnings ratio is 6.72x while Cryo-Cell International's PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.72x versus 1.27x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BTMD
    Biote
    0.72x 6.72x $49M $13.7M
    CCEL
    Cryo-Cell International
    1.27x 498.00x $7.9M $355.8K
  • Which has Higher Returns BTMD or OMCL?

    Omnicell has a net margin of 28% compared to Biote's net margin of -2.6%. Biote's return on equity of -- beat Omnicell's return on equity of 1.73%.

    Company Gross Margin Earnings Per Share Invested Capital
    BTMD
    Biote
    74.26% $0.37 $21.3M
    OMCL
    Omnicell
    41.14% -$0.15 $1.6B
  • What do Analysts Say About BTMD or OMCL?

    Biote has a consensus price target of $6.40, signalling upside risk potential of 56.05%. On the other hand Omnicell has an analysts' consensus of $43.33 which suggests that it could grow by 55.99%. Given that Biote has higher upside potential than Omnicell, analysts believe Biote is more attractive than Omnicell.

    Company Buy Ratings Hold Ratings Sell Ratings
    BTMD
    Biote
    4 0 0
    OMCL
    Omnicell
    4 3 0
  • Is BTMD or OMCL More Risky?

    Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omnicell has a beta of 0.761, suggesting its less volatile than the S&P 500 by 23.879%.

  • Which is a Better Dividend Stock BTMD or OMCL?

    Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BTMD or OMCL?

    Biote quarterly revenues are $49M, which are smaller than Omnicell quarterly revenues of $269.7M. Biote's net income of $13.7M is higher than Omnicell's net income of -$7M. Notably, Biote's price-to-earnings ratio is 6.72x while Omnicell's PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.72x versus 1.14x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BTMD
    Biote
    0.72x 6.72x $49M $13.7M
    OMCL
    Omnicell
    1.14x 60.39x $269.7M -$7M
  • Which has Higher Returns BTMD or PIII?

    P3 Health Partners has a net margin of 28% compared to Biote's net margin of -5.49%. Biote's return on equity of -- beat P3 Health Partners's return on equity of -53.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    BTMD
    Biote
    74.26% $0.37 $21.3M
    PIII
    P3 Health Partners
    -- -$6.28 $293M
  • What do Analysts Say About BTMD or PIII?

    Biote has a consensus price target of $6.40, signalling upside risk potential of 56.05%. On the other hand P3 Health Partners has an analysts' consensus of $8.00 which suggests that it could grow by 23.08%. Given that Biote has higher upside potential than P3 Health Partners, analysts believe Biote is more attractive than P3 Health Partners.

    Company Buy Ratings Hold Ratings Sell Ratings
    BTMD
    Biote
    4 0 0
    PIII
    P3 Health Partners
    1 2 0
  • Is BTMD or PIII More Risky?

    Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BTMD or PIII?

    Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BTMD or PIII?

    Biote quarterly revenues are $49M, which are smaller than P3 Health Partners quarterly revenues of $373.2M. Biote's net income of $13.7M is higher than P3 Health Partners's net income of -$20.5M. Notably, Biote's price-to-earnings ratio is 6.72x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.72x versus 0.01x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BTMD
    Biote
    0.72x 6.72x $49M $13.7M
    PIII
    P3 Health Partners
    0.01x -- $373.2M -$20.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock